Rubicon Research LimitedQuarter ended June 30, 2026 Results & Financial Update
Rubicon Research Limited: Quarter ended June 30, 2026 consolidated results and company financials – revenue ₹534.34 Cr, PAT ₹84.78 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Rubicon Research price & chart
Market price₹1,535.40
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Rubicon Research Quarter ended June 30, 2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Rubicon Research reported consolidated revenue from operations of INR 5,343.38 million for the quarter ended June 30, 2026, marking a robust 51.6% increase compared to INR 3,524.94 million in the corresponding quarter of the previous year.
Profit after tax (PAT) for the quarter grew strongly by 95.8% year-on-year to INR 84.78 million, compared to INR 433.01 million in Q1 FY25, driven by strong operational execution and higher sales volumes in key regulated markets.
Gross margins improved sequentially by 140 basis points to 67.7%, demonstrating resilience against sharp increases in key input costs driven by prevailing geopolitical conditions.
The consolidated financials for the quarter include the results of Arinna Lifesciences Limited from the date of acquisition (April 30, 2026) following the completion of an 85% stake purchase for a total consideration of INR 1,759.17 million.
Operating EBITDA for the quarter reached 24.2%, improving from 23.1% in the previous quarter despite annual employee wage increments kicking in during the period.
R&D expenses stood at INR 600.69 million on a consolidated basis during the quarter, representing about 10.9% of operating revenue as the company continues to invest in its robust product pipeline.
01 · Business model
What does Rubicon Research do?
Rubicon Research Limited is an R&D-driven pharmaceutical formulations manufacturing and marketing company focused on regulated markets, particularly the United States and India.
The company specializes in complex generics, drug-device combinations (such as nasal sprays), and branded formulations, backed by a wide commercial portfolio including active ANDAs and NDAs.
Rubicon operates multiple manufacturing and R&D facilities across India and North America, leveraging an integrated business model spanning early-stage research to direct front-end US distribution via subsidiaries like Validus Pharmaceuticals and Advagen Pharma.
02 · Historical context
What shaped the business before this quarter
Since its inception as a CDO in 1999, Rubicon transitioned through contract manufacturing and out-licensing phases before building its own ANDA portfolio, direct US front-end distribution, and branded specialty products from 2022 onwards.
During the previous financial year ended March 31, 2026, the company raised funds via a fresh issue of equity shares, utilizing proceeds toward the prepayment of borrowings and funding inorganic growth and strategic initiatives.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Quarter ended June 30, 2026 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹534.34 Cr | ₹352.49 Cr | ₹513.92 Cr |
| Total income | ₹540.02 Cr | ₹353.13 Cr | ₹516.53 Cr |
| Profit before tax | ₹110.37 Cr | ₹59.56 Cr | ₹98.69 Cr |
| Profit after tax | ₹84.78 Cr | ₹43.30 Cr | ₹76.79 Cr |
| EPS | ₹5.13 | ₹2.81 | ₹4.66 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations grew 51.6% YoY to INR 5,343.38 million, underpinned by strong demand across the product portfolio, with the top 5 products accounting for 39% and top 10 products accounting for 55% of revenue.
US Dollar revenue reached $55 million for the quarter, up 32% year-on-year from $42 million in Q1 FY26, though showing a slight sequential normalization due to tactical portfolio choices.
What drove margins
Gross margin percentage increased sequentially by 140 bps to 67.7% in Q1 FY27 despite higher key input costs, aided by management's tactical calibration of lower-margin business lines.
Employee benefit expenses rose sequentially to INR 856.66 million, reflecting annual wage increments that traditionally take effect during the first quarter of each financial year.
05 · Demand, customers & order book
Where demand is coming from
Rubicon maintained a strong commercialization rate of 88% across its approved US portfolio, with 76 out of 86 active approved products successfully commercialized.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The group continues to operate primarily in a single business segment focused on the sale of pharmaceutical products as per Ind AS 108.
Geography and market mix
The company maintains strong marketing, sales, and distribution footprints across the United States via subsidiaries like Advagen and Validus, alongside expanding domestic operations.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company’s manufacturing network—including Ambernath, Satara, and newly integrated sites—operates with robust digital and automated quality management systems.
Projects, capex and execution
Subsequent to the quarter end, subsidiary AdvaGen Holdings acquired a USFDA-approved manufacturing facility in East Brunswick, New Jersey, for USD 2.9 million under a court-supervised process to serve as a local US manufacturing footprint.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The company completed the acquisition of an 85% stake in Arinna Lifesciences Limited for INR 1,759.17 million on April 30, 2026, incorporating its CNS-focused domestic formulation business into the consolidated group.
The Board approved the scheme of amalgamation for wholly owned subsidiary Kia Health Tech Private Limited under the fast-track merger route with an appointed date of April 1, 2026.
09 · Reported developments
What changed operationally
The company received 2 new product approvals during Q1 FY27, maintaining a robust pipeline for future growth.
10 · Pressure points & risks
What is not going smoothly
The Pithampur facility underwent an unannounced USFDA inspection resulting in a Form 483 with 2 procedural observations, for which timely corrective responses have been filed.
11 · Items worth noticing
The line items that can distort a quick read
Recorded an insurance claim receipt of INR 36 million on goods lost in transit during the period.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash generated from operating activities for Q1 FY27 was INR 285 million, temporarily affected by delays in receiving significant GST refunds that have begun to normalize post quarter-end.
Capital allocation & funding
Consolidated borrowings stood at INR 3,272 million as of June 30, 2026, compared to INR 2,594 million at the end of March 31, 2026.
13 · Management guidance & targets
What management is targeting from here
Management revised its operating EBITDA margin guidance upwards, stating that for FY27 as a whole, operating EBITDA margins are expected to hold at least at 23%.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Leadership transition
The Board approved leadership changes wherein current CFO Nitin Jajodia will transition to an operational role as Chief Commercial Officer upon the successful handover of the CFO role to Rohit Saraogi, who joined as CFO Designate.
15 · Previous-quarter changes
What changed since the previous quarter
Days of net working capital improved sequentially to 114 days in Q1 FY27 compared to 126 days for the full year FY26.
16 · Key Q&A
The quarter, answered directly
What does Rubicon Research do?
Rubicon Research Limited is an R&D-driven pharmaceutical formulations manufacturing and marketing company focused on regulated markets, particularly the United States and India.
What is the clearest takeaway from Quarter ended June 30, 2026?
Rubicon Research reported consolidated revenue from operations of INR 5,343.38 million for the quarter ended June 30, 2026, marking a robust 51.6% increase compared to INR 3,524.94 million in the corresponding quarter of the previous year.
What drove revenue or demand?
Revenue from operations grew 51.6% YoY to INR 5,343.38 million, underpinned by strong demand across the product portfolio, with the top 5 products accounting for 39% and top 10 products accounting for 55% of revenue.
What mattered most for margins or profitability?
Gross margin percentage increased sequentially by 140 bps to 67.7% in Q1 FY27 despite higher key input costs, aided by management's tactical calibration of lower-margin business lines.
What changed operationally beyond the headline numbers?
The company’s manufacturing network—including Ambernath, Satara, and newly integrated sites—operates with robust digital and automated quality management systems.
What is management guiding or targeting from here?
Management revised its operating EBITDA margin guidance upwards, stating that for FY27 as a whole, operating EBITDA margins are expected to hold at least at 23%.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Commercialization of new plants: Monitor the ongoing ramp-up and commercial operations timeline for the Pithampur facility and the newly acquired New Jersey plant slated for CY2027.
- 02
Integration of Arinna Lifesciences: Track the performance contribution and portfolio synergy realization from the newly consolidated Arinna business.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.